Second-Line TKIs Offer Expanded Treatment Options for Newly Diagnosed Patients with CML

New first-line therapies for patients with CML highlight notable updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for CML at the National Comprehensive Cancer Network® (NCCN®) 16th Annual Conference. HOLLYWOOD, FL - Second generation tyrosine kinase inhibitor (TKI) therapies approved for first-line therapy of chronic myelogenous leukemia (CML) offer newly diagnosed patients an expanded range of treatment options, according to Susan O'Brien, MD, of The Universi...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news